Bernstein lowered the firm’s price target on Insulet (PODD) to $330 from $380 and keeps an Outperform rating on the shares. The firm notes the insulin pump space is getting more competitive as established players make progress on pipelines and newer entrants expand their commercial presence. Investors worry about competitive patch pumps and potential price pressure in the pharmacy channel. Recent Rx data has exacerbated these concerns, and Insulet shares have underperformed, Bernstein adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target lowered to $340 from $380 at Citi
- Insulet price target lowered to $435 from $450 at Canaccord
- Insulet price target raised to $286 from $274 at Barclays
- Insulet: Strong Q4 Execution and Encouraging 2026 Outlook Offset by Valuation and Competitive Pressures, Justifying Hold Rating
- Insulet: Sustained Growth Runway and Underappreciated Long‑Term Upside Support Buy Rating